mCRPC Clinical Trial Monitor

Active Phase 3 mCRPC Programs (2026)

Active Phase 2 Programs

The mCRPC Treatment Landscape in 2026

Metastatic castration-resistant prostate cancer (mCRPC) is defined by disease progression despite castrate levels of testosterone (<50 ng/dL). As of 2026, the approved standard-of-care includes: AR pathway inhibitors (enzalutamide, apalutamide, darolutamide), the CYP17A1 inhibitor abiraterone acetate, taxane chemotherapy (docetaxel, cabazitaxel), lutetium-177 PSMA-617 (Pluvicto) for PSMA-positive mCRPC, radium-223 for bone-metastatic mCRPC, and PARP inhibitors (olaparib, rucaparib) for BRCA-mutated mCRPC.

The key unmet need driving the 2026 clinical trial landscape is resistance to approved therapies — particularly ARPI resistance (most patients progress within 12–18 months on enzalutamide or abiraterone) and the growing post-lutetium PSMA population who have no established treatment options after Pluvicto progression.

The Three Emerging Resistance-Targeting Mechanisms

• CYP11A1 inhibition (opevesostat): Blocks the top of the steroidogenesis cascade, addressing the residual intratumoral androgen synthesis that drives ARPI resistance
• EZH2 inhibition (mevrometostat): Epigenetic reprogramming — EZH2-mediated polycomb silencing is upregulated in CRPC and associated with enzalutamide resistance
• Alpha-particle PSMA radioligand (AAA817): Higher linear energy transfer than beta-emitting Pluvicto; being specifically tested post-Pluvicto progression

Key Questions in mCRPC Research (2026)

1. Can CYP11A1 inhibition overcome ARPI resistance?

Abiraterone targets CYP17A1 (one step in androgen synthesis). Enzalutamide blocks the AR directly. Both leave CYP11A1 — the first enzymatic step converting cholesterol to pregnenolone — intact. Opevesostat's mechanism plugs this upstream bypass. Merck's two Phase 3 trials (NCT06136624, NCT06136650) will provide definitive data on whether this translates to a survival benefit in ARPI-pretreated mCRPC.

2. Is alpha-emitting PSMA RLT the next step after Pluvicto?

After lutetium PSMA-617 approval (VISION trial, OS benefit in PSMA-positive mCRPC), the next clinical question is: what happens after progression? Novartis's AAA817 actinium-225 trial directly tests whether alpha-PSMA can provide meaningful benefit in patients who exhausted beta-PSMA. Alpha particles have ~1,000× higher cell-killing efficiency per decay vs. beta particles, but produce more off-target effects if PSMA is expressed in normal tissues. The NEPTUNE Phase 2/3 trial will be closely watched by the nuclear oncology community.

3. Where do ADCs fit in the mCRPC armamentarium?

ADCs have transformed breast cancer and are emerging in prostate. The two active mCRPC ADC programs in 2026 target distinct antigens: Dato-DXd (TROP2, AstraZeneca) which has approvals in breast/lung cancer is being explored in mCRPC; ifinatamab deruxtecan (STEAP2, Merck) specifically targets a prostate-enriched antigen. Neither is approved yet; both are in Phase 1/2. The critical question is whether the TROP2/STEAP2 expression profile in mCRPC is sufficient to drive clinical benefit.

FAQ: mCRPC Clinical Trials

What does "castration-resistant" mean in prostate cancer?

Castration-resistant prostate cancer (CRPC) means the cancer is growing despite hormone therapy (androgen deprivation therapy, ADT) that has reduced testosterone to castrate levels (<50 ng/dL). "Castration" refers to surgical or medical elimination of testicular androgen production. Resistance develops because prostate cancer cells develop mechanisms to survive and grow with minimal androgen stimulation — including AR amplification, AR splice variants (AR-V7), and intratumoral de novo androgen synthesis. mCRPC adds the "metastatic" qualifier — disease that has spread to lymph nodes, bone, or visceral organs.

Who are typical participants in mCRPC trials?

Most mCRPC trials require: confirmed CRPC on ongoing ADT; castrate testosterone levels; measurable disease or rising PSA; ECOG performance status 0–2; and organ function adequate for the investigational therapy. PSMA-targeted trials additionally require PSMA-positive scans (68Ga-PSMA-11 or 18F-DCFPyL PET). PARP inhibitor trials typically require somatic or germline HRR mutations (olaparib: BRCA1/2; broader HRR panels for some studies). Some trials specify prior therapy (e.g., post-ARPI, post-Pluvicto).

How does PSMA expression affect eligibility for lutetium PSMA trials?

PSMA (Prostate-Specific Membrane Antigen) expression is heterogeneous in mCRPC — roughly 75–80% of mCRPC patients have PSMA-positive tumors at a level sufficient for targeted therapy. The VISION trial (which supported Pluvicto approval) required PSMA-positive PET with no PSMA-negative lesions larger than 2.5 cm (liver) or 1.0 cm (other sites). PSMA-negativity (or PSMA-negative escape lesions) is an exclusion for most radioligand trials. The Novartis AAA817 Phase 2/3 trial specifically recruits patients who have progressed on 177Lu-PSMA-617, so PSMA status post-Pluvicto is a key enrollment consideration.

How is DataLookout different from setting a ClinicalTrials.gov alert for "prostate cancer"?

A broad ClinicalTrials.gov alert for "prostate cancer" generates dozens of new entries weekly — most irrelevant to mCRPC (localized disease trials, PSA screening studies, quality of life studies). DataLookout's daily digest focuses on Phase 2/3 industry-sponsored trials with active recruitment — the signal, not the noise. You can set separate profiles for mCRPC Phase 3 programs and mCRPC PSMA-targeting trials and receive a combined digest without duplicates.

Related Pages

• Prostate Cancer Clinical Trials (all stages)
• Bladder Cancer / Urothelial Carcinoma Trials
• HER2-Positive Cancer Clinical Trials
• Pancreatic Cancer Clinical Trials